DEPO PROVERA

Glavne informacije

  • Zaščiteno ime:
  • DEPO PROVERA 150 mg/ml suspenzija za injiciranje
  • Farmacevtska oblika:
  • suspenzija za injiciranje
  • Sestava:
  • medroksiprogesteron 150 mg / 1 ml
  • Pot uporabe:
  • Način uporabe nedoločen
  • Enote v paketu:
  • škatla z 1 ampulo z 1 ml suspenzije za injiciranje
  • Tip zastaranja:
  • / - Način/režim izdaje ni določen.
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Alopatska drog

Dokumentov

Lokalizacija

  • Na voljo v:
  • DEPO PROVERA 150 mg/ml suspenzija za injiciranje
    Slovenija
  • Jezik:
  • slovenščina

Terapevtski podatki

  • Terapevtska skupina:
  • medroksiprogesteron

Drugi podatki

Stanje

  • Source:
  • JAZMP - Javna agencija RS za zdravila in medicinske pripomočke - Slovenia Medicines Agency
  • Status dovoljenje:
  • Zdravilo z začasnim dovoljenjem za vnos/uvoz s seznama EZ ali NP
  • Številka dovoljenja:
  • 842-191/2017
  • Datum dovoljenje:
  • 07-08-2017
  • Zadnja posodobitev:
  • 19-01-2018

2-10-2018

Garderie Dépôt recalls Dream on Me Portable Cribs

Garderie Dépôt recalls Dream on Me Portable Cribs

The distance between the top surface of the lowest fixed side and the top surface of the mattress support is lower than what is required by law, posing a fall hazard.

Health Canada

27-7-2018

EU/3/09/645 (Camurus AB)

EU/3/09/645 (Camurus AB)

EU/3/09/645 (Active substance: Octreotide chloride (lipid depot solution)) - Transfer of orphan designation - Commission Decision (2018)5047 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/010/09/T/03

Europe -DG Health and Food Safety

10-7-2018

DepoCyte (Pacira Limited)

DepoCyte (Pacira Limited)

DepoCyte (Active substance: Cytarabine) - Centralised - Withdrawal - Commission Decision (2018)4490 of Tue, 10 Jul 2018

Europe -DG Health and Food Safety

29-5-2018

EU/3/09/645 (Novartis Europharm Limited)

EU/3/09/645 (Novartis Europharm Limited)

EU/3/09/645 (Active substance: Octreotide chloride (lipid depot solution)) - Transfer of orphan designation - Commission Decision (2018)3397 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/010/09/T/02

Europe -DG Health and Food Safety